Data from the BEXMAB study marks a significant milestone for next-generation cancer immunotherapies TURKU, FI / ACCESS Newswire / April 24, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN), a ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from the ...

TURKU, FI / ACCESS Newswire / April 17, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel imm ...

The treatment of asthma and allergic rhinitis using unique, humanized anti ... effects of these monoclonal antibodies in neutralizing free IgE and inhibiting IgE production by B cells, several ...

Here, we report the development of a whole sequence-humanized Gs-coupled DREADD, hM3Ds ... The membranes were blocked at room temperature for 1 h and then incubated with anti-HA antibody (BioLegend, ...

(HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its independently developed IL-4Rα ...

Creative Biolabs is advancing non-IgG antibody solutions across IgE, IgM, and IgA platforms, offering sophisticated production and purification technologies that could significantly impact ...

Their paper, “A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response,” was recently accepted and published in the Science Translational Medicine journal.

Their paper, "A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response,” was recently accepted and published in the Science Translational Medicine journal.

Their paper, “A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response,” was recently accepted and published in the Science Translational Medicine journal.